Phosphogliv 2.5g 5's lyophilisates for preparing a solution for intravenous injection in ampoules sol.

The instruction for medical use of FOSFOGLIV® medicine the Trade name of Fosfogliv® the International unlicensed name Is not present the Dosage form Lyophilisate for preparation of solution for intravenous administration of 2.5 g Structure One bottle contains active agents: phospholipids (Lipoid C 100) (in terms of 100% substance) 0.50 g, glycyrrhizic acid trinatriyevy salt (sodium glycyrrhizinate) 0.20 g, excipient: a maltose, composition of solvent on one ampoule: water for injections. The description the Lyophilized weight from white till light yellow color. Solvent - flavourless colourless transparent liquid and taste. Pharmacotherapeutic group Drugs for treatment of diseases of a liver and biliary tract. Drugs for treatment of diseases of a liver. The ATX A05BA code Pharmacological Fosfatidilkholin properties (main component of phospholipids) is the basic structural element of cellular and intracellular membranes, is capable to restore their structure and functions at damage, having cytoprotective effect. Normalizes proteinaceous and lipidic exchanges, prevents loss by hepatocytes of enzymes and other active agents, restores function of a liver, inhibits forming of connective tissue, reducing risk of developing of fibrosis and cirrhosis. Glycyrrhizic acid possesses anti-inflammatory action, suppresses a reproduction of viruses in a liver and other bodies due to stimulation of products of interferon, increase in phagocytosis, increase in activity of natural cells killers. Has hepatoprotective effect thanks to antioxidant and membrane stabilizing activity. Glycyrrhizic acid exponentiates action of endogenous glucocorticosteroids, having anti-inflammatory and antiallergic effect at non-infectious damages of a liver. At damages of skin due to membrane stabilizing and anti-inflammatory action limits distribution of process and promotes regress of a disease. The indication to use - a viral hepatitis (sharp and chronic) - fatty degeneration of a liver (hepatosis) - other damages of a liver (medicinal, alcoholic, toxic) - cirrhosis - psoriasis the Route of administration and doses to Adults and children is more senior than 12 years. Intravenously, previously having dissolved lyophilisate in 10 ml of water for injections. To carry out intravenous administration slowly. Enter 10 ml daily 2 times a day in the morning and in the evening within 10 days with the subsequent transition to oral administration of drug in the form of capsules. Duration of a course can be increased according to the recommendation of the doctor. Contraindications - hypersensitivity to drug components - pregnancy and the period of a lactation - children's age up to 12 years Side effects - appearance of skin rash (at the increased individual sensitivity) is possible which disappears after drug withdrawal - when exceeding daily doses the delay of sodium and liquid, hypostases - increase in arterial blood pressure - a hypopotassemia can be noted At emergence of the specified symptoms, depending on their expressiveness, it is necessary to reduce a dose of drug and/or to appoint Spironolactonum of 50-100 mg a day. Medicinal interactions Contents of a bottle cannot be mixed with other solutions. For dissolution to use only water for injections. It is forbidden to use normal saline solution of sodium of chloride or solution of glucose for drug cultivation. Special instructions not to administer 20 ml of the drug in one stage. To carry out introduction of a daily dose of drug only in two steps, in the morning and in the evening. Features of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms. Are not described. Overdose of Cases of overdose of drug it was not noted. Glycyrrhizic acid which is a part of drug in high doses can cause the pseudo-corticosteroid effect representing increase in level of glucocorticosteroids and mineralokortikoid in blood. It leads to a delay of sodium and reduction of potassium in an organism and, as a result, increase in level of arterial blood pressure, a water delay in an organism. A form of release and packing On 2.5 g of drug in bottles glass medical import, made of light-protective glass, hermetically corked by import rubber bungs, rolled by aluminum caps and closed by plastic protective caps or corked by the caps combined. On 10 ml of solvent (water for injections) in ampoules import, made of transparent glass. On a bottle and an ampoule paste the self-adhesive label. 5 bottles of drug complete with 5 ampoules of solvent place in blister strip packaging. On one planimetric packing together with the instruction for medical use in the state and Russian languages place in a pack from cardboard. Storage conditions In the place protected from light at a temperature not over 25 ºС. (drug) At a temperature from 0 °C to 25 °C. Is not subject to freezing (solvent). To store out of children's reach! Period of storage 2 years (drug) 4 years (solvent). Not to apply after the expiration date specified on packing! Prescription status According to the prescription JSC Pharmstandard-UfaVITA Producer 450077, Russia, Ufa, Hudayberdin St., 28 Ph./fax: (347) 272 92 85, www.pharmstd.ru the Owner of the registration certificate of JSC Pharmstandard-UfaVITA, Russia the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products and responsible for post-registration observation of safety of medicine of Karagandinsky pharmatsevtichesky komplex LLP 100009, Republic of Kazakhstan, Karaganda, Botanicheskaya St., 12